You have reached the guest article limit.
Unlock more of the IIPLA newsroom by signing in with SSO or joining as a member.
Google SSO gives you the quickest path into the IIPLA newsroom, your reading access, and member-level continuity across articles. The full login page is still available if you prefer another option.
Intellectual Property Office Announces Application on the 4th—Finalization if No Objection Just Two Months After Application—Government Support Requested in January Not Only Engli…
Unlock more of the IIPLA newsroom by signing in with SSO or joining as a member.
Samyang Foods has achieved a significant milestone in its quest to secure domestic trademark rights for the English name 'Buldak,' following an expedited review by the Intellectual Property Office. The move comes as the company faces a proliferation of imitation products overseas and seeks to strengthen its global bra…
Celadyne Technologies, a startup emerging from UT Austin’s Cockrell School of Engineering, has received a $250,000 investment from the UT Seed Fund. The funding, managed by Discovery to Impact, will support Celadyne’s development of advanced membrane materials for hydrogen fuel cells and electrolyzers, aiming to addre…
Winston & Strawn SearchProfessionalsCapabilitiesInsights & NewsCareersLocationsAbout UsAlumniOpportunity & InclusionPro BonoCorporate Social ResponsibilityStay Connected:facebookinstagramlinkedintwitteryoutubeInsights & NewsRec…
Law360 Try our Advanced Search for more refined results Law360 | The Practice of Law Access to Justice Aerospace & Defense Appellate Asset Management Banking Bankruptcy Benefits California Cannabis Capital Markets Class Action Colorado Commercial Contracts Co…
Bulgaria has been removed from the intellectual property protection watch list under the so-called "Special 301" Report following coordinated efforts by Bulgaria's Prosecution Office and the National Investigation Service, in cooperation with the United States Department of Justice and the United States Department of…
When the acting attorney general moved state-licensed medical marijuana and FDA-approved marijuana-containing products from Schedule I to Schedule III, the headlines focused on banking, taxation, and what the change might mean for operators day to day. But one consequential — and underreported — area of impact is inte…